Calcitonin transdermal - TransPharma

Drug Profile

Calcitonin transdermal - TransPharma

Alternative Names: Transdermal salmon calcitonin; ViaDerm-Calcitonin; ViaDor-Calcitonin

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransPharma Medical
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Musculoskeletal pain; Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-pain in Israel (Transdermal, Patch)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis in Israel (Transdermal, Patch)
  • 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top